TG4010 and Nivolumab in Patients With Lung Cancer

Inclusion Criteria: * Histologically confirmed non-squamous NSCLC; patients with adenocarcinoma must have had epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutational testing; those with an actionable mutations/rearrangements are excluded * Stage IIIB or IV patients must have progressed after a platinum based chemotherapy; a maximum of 3 previous systemic regimens are allowed (one regimen can be a tyrosine kinase inhibitor); patients with stage I-IIIB NSCLC who have progressed within 6 months of a full dose platinum based regimen as adjuvant therapy or with radiotherapy are eligible; patients who received weekly low dose chemotherapy with radiation only are not eligible * At least one measurable lesion by computed tomography (CT) scan or magnetic resonance imaging (MRI) based on RECIST version 1.1 * Performance status (PS) 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale * Minimum life expectancy of 3 months * Hemoglobin \>= 10.0 g/dL * White blood cells (WBC) \>= 3.0 x 10\^9/L * Neutrophils \>= 1.5 x 10\^9/L * Total lymphocyte count \>= 0.5 x 10\^9/L * Platelet counts \>= 100 x 10\^9/L * Serum alkaline phosphatase =\< 3 x upper limit of normal (ULN) in absence of liver or bone metastases and =\< 5 x ULN in patients with documented bone or liver metastases * Total bilirubin =\< 1.5 x ULN * Serum transaminases (alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\]) =\< 2.5 x ULN in the absence of liver metastases a…